25.01.2013 Views

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

30 <strong>Cancer</strong> <strong>Immune</strong> Therapie: Current <strong>and</strong> Future Strategies<br />

<strong>Edited</strong> <strong>by</strong> G. <strong>Stuhler</strong> <strong>and</strong> P. <strong>Walden</strong><br />

Copyright # 2002 Wiley-VCH Verlag GmbH & Co. KGaA<br />

ISBNs: 3-527-30441-X (Hardback); 3-527-60079-5<br />

(Electronic)<br />

3<br />

Processing <strong>and</strong> Presentation of Tumor-associated Antigens<br />

Peter-M. Kloetzel <strong>and</strong> Alice Sijts<br />

3.1<br />

The Major Histocompatibility Complex (MHC) Class I Antigen-Processing Pathway<br />

As part of the vertebrate immune surveillance system cytotoxic T cells recognize antigens<br />

which are bound <strong>by</strong> MHC class I proteins. To allow binding to MHC class I molecules<br />

a protein has to be proteolytically processed to peptides. The recognition of<br />

the MHC±peptide complex on the plasma membrane <strong>by</strong> a T cell receptor (TCR)<br />

which is specific for a given antigenic peptide bound to a specific MHC class I molecule<br />

eventually leads to T cell activation [1].<br />

Considering the complexity of the MHC class I sequence motifs, any proteolytic system<br />

involved in the generation of immuno-dominant MHC class I epitopes has to be<br />

able to produce peptides of the appropriate size (8±10 residues) <strong>and</strong> amino acid sequence<br />

diversity, <strong>and</strong> it has to be able to generate peptides with defined C-terminal<br />

anchor residues in sufficient efficiency from a large variety of different proteins in<br />

the cytosol <strong>and</strong> nucleus. Today it is widely accepted that the proteasome system is responsible<br />

for the generation of the majority MHC class I lig<strong>and</strong>s [2±4].<br />

The proteasome is the major cytosolic protease complex in eukaryotic cells. It is composed<br />

of a proteolytically active core, i.e. the 20S proteasome <strong>and</strong> two 19S regulator<br />

complexes which attach to both sides of the barrel-shaped 20S proteasome. The complex<br />

formed <strong>by</strong> the cylinder-shaped 20S proteasome <strong>and</strong> the two regulators is called<br />

the 26S proteasome. The 20S proteasome consists of 14 non-identical subunits ranging<br />

in molecular weight from 31 to 21 kDa <strong>and</strong> is composed of four stacked rings of<br />

seven subunits each. The seven different a subunits form the two outer rings, while<br />

the two inner rings are formed <strong>by</strong> the seven different b subunits [3]. The proteolytically<br />

active sites are restricted to the lumen of the cylinder <strong>and</strong> are formed <strong>by</strong> three of<br />

the seven b subunits, i. e. subunits d (b1), Z (b2) <strong>and</strong> MB1 (b5). In total, the 20S proteasome<br />

therefore possesses six active sites within the two inner b rings [5, 6].<br />

Proteasome function can be modulated through the interaction with several regulatory<br />

proteins <strong>and</strong> in order to enter the catalytic chamber protein substrates have to be<br />

in an unfolded or extended conformation [7, 8]. Unfolding of substrates is thought to<br />

be performed <strong>by</strong> the six ATPases of the 19S regulator complex which directly attach<br />

to the 20S proteasome <strong>and</strong> form the so-called base structure of the 19S regulator.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!